

**IN THE HIGH COURT OF JUSTICE  
BUSINESS AND PROPERTY COURTS OF ENGLAND & WALES  
INTELLECTUAL PROPERTY LIST (ChD)  
PATENTS COURT**

**Claim No. HP-2022-000016**

**B E T W E E N:**

**PFIZER LIMITED**

Claimant

**– and –**

**(1) GLAXOSMITHKLINE BIOLOGICALS S.A.**  
(a company incorporated under the laws of Belgium)

**(2) ID BIOMEDICAL CORPORATION OF QUEBEC**  
(a company incorporated under the laws of Quebec, Canada)

Defendants

---

**ANNEX 1 TO THE  
STATEMENT OF GROUNDS FOR AMENDMENT**

---

1. A recombinant respiratory syncytial virus (RSV) antigen which assembles into a trimer, comprising a soluble F protein polypeptide comprising an F<sub>2</sub> domain and an F<sub>1</sub> domain of an RSV F protein polypeptide and comprising an amino acid sequence comprising a heterologous trimerization domain positioned C-terminal to the F<sub>1</sub> domain that stabilizes the prefusion conformation of the F protein.
2. The recombinant RSV antigen of claim 1, further comprising a signal peptide.
3. The recombinant RSV antigen of any one of claims 1-2, wherein the heterologous trimerization domain comprises a coiled-coil domain.
4. A recombinant nucleic acid that encodes the recombinant RSV antigen of any one of claims 1-3.
5. An immunogenic composition comprising the recombinant RSV antigen of any one of claims 1-3, and a pharmaceutically acceptable carrier or excipient.
6. The immunogenic composition of claim 5 further comprising an adjuvant.
- ~~7. The immunogenic composition of claim 6, wherein the adjuvant comprises at least one of: 3D-MPL, QS21, an oil-in-water emulsion, and Alum.~~
8. ~~7.~~ The use of the RSV antigen of any one of claims 1-3 or the recombinant nucleic acid of claim 4 in the preparation of a medicament for treating an RSV infection.

9. 8. The recombinant RSV antigen of any one of claims 1-3 or the immunogenic composition of any one of claims 5-76 for use in the prevention or treatment of RSV-associated diseases.